停止复发缓解型和进展型多发性硬化症的疾病修正治疗。
Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis.
机构信息
Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany.
Brain and Mind Centre, University of Sydney, Camperdown.
出版信息
Curr Opin Neurol. 2021 Aug 1;34(4):598-603. doi: 10.1097/WCO.0000000000000960.
PURPOSE OF REVIEW
To assess the reasons for considering discontinuation of disease-modifying therapies (DMTs)in patients with multiple sclerosis (MS). Relevant aspects of the natural history, pathology, and immunology are analyzed.
RECENT FINDINGS
A number of retrospective observational studies in aggregate indicate that stopping DMTs may be attempted in older individuals with stable disease. Prognostic factors have been identified informing about the risk of recurrence of disease activity after DMT discontinuation.
SUMMARY
Several clinical scenarios provide a rationale to stop DMTs in people with MS. Cumulative evidence has been gathered recently allowing us to more precisely weigh the risks against the benefits. This information aids in the decision process.
目的综述
评估多发性硬化症 (MS) 患者停止疾病修正治疗 (DMT) 的原因。分析了自然史、病理学和免疫学的相关方面。
最近的发现
大量回顾性观察研究表明，对于病情稳定的老年患者，可以尝试停止 DMT。已经确定了预后因素，这些因素可以预测 DMT 停药后疾病活动复发的风险。
总结
多种临床情况为 MS 患者停止 DMT 提供了依据。最近积累了大量证据，使我们能够更精确地权衡风险与收益。这些信息有助于决策过程。
Zotero 插件